Literature DB >> 25107915

Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.

Hae-Yun Jung1, Laurent Fattet1, Jing Yang1,2.   

Abstract

During tumor development, tumor cells constantly communicate with the surrounding microenvironment through both biochemical and biophysical cues. In particular, the tumor microenvironment can instruct carcinoma cells to undergo a morphogenesis program termed epithelial-to-mesenchymal transition (EMT) to facilitate local invasion and metastatic dissemination. Growing evidence uncovered a plethora of microenvironmental factors in promoting EMT, including proinflammatory cytokines secreted by locally activated stromal cells, hypoxia conditions, extracellular matrix components, and mechanical properties. Here, we review various biochemical and biophysical factors in the tumor microenvironment that directly impinge upon the EMT program. Specifically, cytokines such as TGFβ, TNFα, and IL6 and hypoxia are capable of inducing EMT in various tumors. Several extracellular matrix (ECM) proteins, including collagen-I, fibronectin, and hyaluronan, and ECM remodeling via extracellular lysyl oxidase are also implicated in regulating EMT. In preclinical studies and ongoing clinical trials, targeting these tumor microenvironmental signals has shown promises in halting tumor progression in various human cancers. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25107915      PMCID: PMC4320988          DOI: 10.1158/1078-0432.CCR-13-3173

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.

Authors:  Gianluca Storci; Pasquale Sansone; Sara Mari; Gabriele D'Uva; Simona Tavolari; Tiziana Guarnieri; Mario Taffurelli; Claudio Ceccarelli; Donatella Santini; Pasquale Chieco; Kenneth B Marcu; Massimiliano Bonafè
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model.

Authors:  Mariko Kyutoku; Yoshiaki Taniyama; Naruto Katsuragi; Hideo Shimizu; Yasuo Kunugiza; Kazuma Iekushi; Nobutaka Koibuchi; Fumihiro Sanada; Yoshihiro Oshita; Ryuichi Morishita
Journal:  Int J Mol Med       Date:  2011-05-26       Impact factor: 4.101

3.  A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Derek G Power; Hedy L Kindler; Kyle D Holen; Margaret M Kemeny; David H Ilson; Laura Tang; Marinela Capanu; John J Wright; David P Kelsen
Journal:  Invest New Drugs       Date:  2010-06-25       Impact factor: 3.850

4.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

Authors:  Srinivasan Madhusudan; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Trivadi S Ganesan
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  IKK(α) controls canonical TGF(ß)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells.

Authors:  Martina Brandl; Barbara Seidler; Ferdinand Haller; Jerzy Adamski; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  J Cell Sci       Date:  2010-11-16       Impact factor: 5.285

6.  Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.

Authors:  Chul Jang Kim; Kanami Sakamoto; Yukihiro Tambe; Hirokazu Inoue
Journal:  Int J Oncol       Date:  2011-04-05       Impact factor: 5.650

7.  TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug.

Authors:  Eva Slabáková; Zuzana Pernicová; Eva Slavíčková; Andrea Staršíchová; Alois Kozubík; Karel Souček
Journal:  Prostate       Date:  2011-02-14       Impact factor: 4.104

8.  Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.

Authors:  Chia-Wei Li; Weiya Xia; Longfei Huo; Seung-Oe Lim; Yun Wu; Jennifer L Hsu; Chi-Hong Chao; Hirohito Yamaguchi; Neng-Kai Yang; Qingqing Ding; Yan Wang; Yun-Ju Lai; Adam M LaBaff; Ting-Jung Wu; Been-Ren Lin; Muh-Hwa Yang; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2012-01-17       Impact factor: 12.701

9.  IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2.

Authors:  Ying-Wen Su; Tong-Xin Xie; Daisuke Sano; Jeffrey N Myers
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition.

Authors:  Jennifer L Leight; Michele A Wozniak; Sophia Chen; Michelle L Lynch; Christopher S Chen
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

View more
  123 in total

Review 1.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 2.  Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Authors:  Nicholas F Dybdal-Hargreaves; April L Risinger; Susan L Mooberry
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

3.  Endothelial-to-mesenchymal transition drives atherosclerosis progression.

Authors:  Pei-Yu Chen; Lingfeng Qin; Nicolas Baeyens; Guangxin Li; Titilayo Afolabi; Madhusudhan Budatha; George Tellides; Martin A Schwartz; Michael Simons
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

Review 4.  The Hidden Conundrum of Phosphoinositide Signaling in Cancer.

Authors:  Narendra Thapa; Xiaojun Tan; Suyong Choi; Paul F Lambert; Alan C Rapraeger; Richard A Anderson
Journal:  Trends Cancer       Date:  2016-06-20

5.  Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma.

Authors:  Hung-Yi Liu; Murray Korc; Chien-Chi Lin
Journal:  Biomaterials       Date:  2018-01-08       Impact factor: 12.479

6.  PIPKIγ and talin couple phosphoinositide and adhesion signaling to control the epithelial to mesenchymal transition.

Authors:  N Thapa; X Tan; S Choi; T Wise; R A Anderson
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

Review 7.  Emerging molecular basis of hematogenous metastasis in gastric cancer.

Authors:  Jing Zhong; Yan Chen; Liang-Jing Wang
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

8.  Wingless modulates activator protein-1-mediated tumor invasion.

Authors:  Shiping Zhang; Xiaowei Guo; Honggui Wu; Ying Sun; Xianjue Ma; Jikai Li; Qian Xu; Chenxi Wu; Qiwen Li; Cizhong Jiang; Wenzhe Li; Margaret S Ho; Zhongwei Lv; Lei Xue
Journal:  Oncogene       Date:  2019-01-25       Impact factor: 9.867

9.  ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.

Authors:  Mingyang Liu; Jingxuan Yang; Yuqing Zhang; Zhijun Zhou; Xiaobo Cui; Liyang Zhang; Kar-Ming Fung; Wei Zheng; Felicia D Allard; Eric U Yee; Kai Ding; Huanwen Wu; Zhiyong Liang; Lei Zheng; Martin E Fernandez-Zapico; Yi-Ping Li; Michael S Bronze; Katherine T Morris; Russell G Postier; Courtney W Houchen; Jing Yang; Min Li
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

Review 10.  Obstructive sleep apnea and cancer: Epidemiologic links and theoretical biological constructs.

Authors:  David Gozal; Ramon Farré; F Javier Nieto
Journal:  Sleep Med Rev       Date:  2015-06-03       Impact factor: 11.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.